Coronavirus Pandemic

Covid-19: India says homegrown mRNA vaccine safe in early trial

Filed on August 24, 2021
Photo: Reuters

Government authorities have approved further studies to test the vaccine's efficacy in a larger population

Indian pharmaceutical firm Gennova Biopharmaceuticals' Covid-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said on Tuesday.

Government authorities have also approved further studies to test the vaccine's efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India.

The company's vaccine development, partly funded by the government, will utilise the clinical trial network under the biotechnology department of the Ministry of Science and Technology.


>> India: Covid third wave likely to peak in October, experts say

>> Covid vaccine: India's Covaxin 93.4% effective against severe infection

Gennova is also investing in scaling up its vaccine manufacturing capacity, the government statement added.

Its parent firm, Emcure Pharmaceuticals, filed draft papers with the market regulator for an initial public offering last week.

ERROR: Macro /ads/dfp-ad-article-new is missing!
MORE FROM Coronavirus Pandemic
MORE FROM Khaleej Times
CurrentRequestUnmodified: /coronavirus-pandemic/covid-19-emirates-skycargo-first-carrier-to-transport-50-million-vaccines macro_action: article, macro_profile: ,1913,1000 macro_adspot:
KT App Download
khaleejtimes app

All new KT app
is available
for download:

khaleejtimes - android khaleejtimes - ios khaleejtimes - HUAWEI AppGallery